文献速递胸部肿瘤头颈与中枢神经肿瘤

利用分子标志物的演进策略靶向非小细胞肺癌中枢神经系统转移:综述

Targeting CNS Metastases in Non-Small Cell Lung Cancer With Evolving Approaches Using Molecular Markers: A Review.
PubMed 文献 · JAMA Oncol · 2025-01-01

本综述指出高达50%的晚期非小细胞肺癌患者病程中出现中枢神经系统转移,EGFR、ALK、ROS1、RET突变者可优先用CNS穿透性靶向治疗,孤立CNS进展可考虑放疗并继续原系统治疗,其他突变及免疫治疗数据尚不明确,需多学科个体化决策。

要点

  • EGFR、ALK、ROS1、RET突变者可优先用CNS穿透性靶向治疗处理CNS转移。
  • 孤立CNS进展时可考虑对进展病灶放疗并继续原系统治疗。
  • 其他突变及检查点抑制剂患者CNS疗效数据尚不明确,早期放疗或需整合入计划。

核心结论

  • CNS转移治疗应个体化,综合考虑分子检测结果、系统治疗CNS穿透性、患者特征及多学科讨论。
  • 需进一步研究CNS转移的克隆演化及开发具CNS疗效的新疗法。

研究设计与样本

  • 综述,总结多项临床试验关于靶向治疗对CNS转移的疾病控制证据。

主要发现

  • 高达50%的晚期非小细胞肺癌患者病程中出现CNS转移(脑实质或软脑膜)。
  • EGFR、ALK、ROS1、RET突变者CNS转移可先用CNS穿透性靶向治疗,再考虑放疗。
  • 孤立CNS进展时可考虑对进展病灶放疗并继续原系统治疗。
  • 其他突变及检查点抑制剂患者系统治疗对未治疗CNS转移是否足够尚不明确,早期放疗或需整合入计划。

临床怎么用

  • EGFR、ALK、ROS1、RET突变CNS转移可先用CNS穿透性靶向治疗,再考虑放疗。
  • 孤立CNS进展可考虑对进展病灶放疗并继续原系统治疗。
  • 其他突变及检查点抑制剂患者CNS疗效数据尚不明确,早期放疗或需整合入治疗计划。
  • 治疗应个体化,考虑分子检测、CNS穿透性、患者特征及多学科讨论。

局限性

  • 其他分子改变及检查点抑制剂患者中,系统治疗对未治疗CNS转移是否足够数据尚不明确。
  • 需进一步研究CNS转移的克隆演化及开发具CNS疗效的新疗法。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Central nervous system (CNS) metastases presenting as either brain parenchymal metastases or leptomeningeal metastases are diagnosed in up to 50% of patients with advanced non-small cell lung cancer during their disease course. While historically associated with a poor prognosis due to limited treatment options, the availability of an increasing number of targeted therapies with good CNS penetration has significantly improved clinical outcomes for these patients. This has occurred in parallel with a more nuanced understanding of prognostic factors. OBSERVATIONS: Multiple clinical trials have reported that disease control can be observed with targeted therapies with adequate CNS penetration, particularly for patients with molecular alterations in EGFR, ALK, ROS1, and RET. For these tumors, systemic targeted therapy may be used first for the management of CNS metastases, prior to considering radiation therapy (RT). At the time of isolated progression in the CNS, RT may be considered for the progressing lesions with continuation of the same systemic therapy. For other molecular alterations as well as for patients treated with checkpoint inhibitors, data are not yet clear if systemic therapy is sufficient for untreated CNS metastases, and early RT may need to be integrated into the treatment planning. An increasing number of studies investigate the role that emerging techniques, such as the sequencing of tumor DNA from resected brain metastases tissue or cerebrospinal fluid or radiomics-based analysis of CNS imaging, can play in guiding treatment approaches. CONCLUSIONS AND RELEVANCE: With multiple generations of targeted therapies now available, the treatment for CNS metastases should be tailored to the patients with consideration given to molecular testing results, CNS penetrance of systemic therapy, patient characteristics, and multidisciplinary review. More research is needed in understanding the clonal evolution of CNS metastases, and the development of novel therapeutics with CNS efficacy.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Malhotra J, Mambetsariev I, Gilmore G, et al. Targeting CNS Metastases in Non-Small Cell Lung Cancer With Evolving Approaches Using Molecular Markers: A Review. JAMA Oncol. 2025. PMID: 39602134. doi:10.1001/jamaoncol.2024.5218

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。